Phesi’s artificial intelligence (AI) driven platform, Trial Accelerator, has reached a milestone and now contains global data from more than 100 million patients.
The latest indepth report from the AI-centric analytics provider reveals nearly half of US cancer clinical studies enroll no Latino patient participants.
The company’s analysis of 2.5m patients worldwide suggest a growing proportion of younger patients, with implications for future study design and deployment.
The company’s analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the country’s borders.
The company’s analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Patient data from the clinical solutions company indicates that gains in recruitment of Black participants is outpacing that of patients from other groups.
According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
The virtual clinical development firm’s analysis of patient profiles reflects obesity is the most significant indicator for severity in those under 40.
A leader from the clinical development services provider recommends using industry modal values to avoid protocol amendments, enrollment problems and more.
The two organizations will collaborate on development of synthetic arms for clinical studies, drawing from millions of patient records and trial subject.
A recent study from the clinical research services firm indicates the pandemic continues to significantly impact clinical trial sites around the globe.
A leader from the clinical development services firm recommends clinical trials change their tack to avoid costly clinical trial interruptions in the face of the pandemic.
The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
